Valbonne, France, May 26, 2015 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces results of its annual general meeting of shareholders held in Valbonne, France.
The quorum amounted to over 85 per cent, with a number of 9,965,370 expressed votes, out of a total 11,644,695 voting rights.
All resolutions were voted in accordance with recommendations from the board of directors.
Details of votes are available on the company’s website: www.txcell-finance.com.
During the meeting, Mr. Thibaut Roulon, was appointed a member of the board of directors as a representative of Bpifrance Participations.
“The general meeting was a good opportunity for the shareholders to reiterate their support to the strategy set by the board of directors and executed by the management at TxCell,” said François Meyer, Chairman of the Board of Directors, TxCell. “Combining a solid scientific grounding, more than 115 patents, a platform with the first two innovative products in development and a first pharma partnership, TxCell has all the ingredients to succeed in at an ideal time where cellular immunotherapy is rapidly gaining momentum.”
“As explained today to our shareholders, Ovasave(R), our lead product, is currently being tested in one of the most ambitious clinical trials ever conducted in Europe with a personalized cellular therapy product. We expect data from this trial, conducted in refractory Crohn’s disease, in 2017. These data will be important for the further validation of ASTrIA, our first product platform of antigen specific regulatory T-cells (Ag-Tregs),” said Stéphane Boissel, CEO, TxCell. “Encouraged by this pioneering work on regulatory T cells, a second innovative product platform based on engineered regulatory T cells (CAR-Treg) is currently being explored. This platform would be a good complement to ASTrIA as it would broaden the scope of diseases addressable by TxCell’s technologies, for the benefits of the medical community and of patients.”
About TxCell
TxCell develops innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary product platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave(R) in refractory Crohn’s disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell has a strategic partnership for the development of Ovasave with the Swiss company Trizell Holding SA and Ferring International Center remains the intended final commercializing party. Both companies are affiliates of the Dr Frederik Paulsen Foundation. TxCell’s second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. A first clinical study with this product is planned to start in 2015. Listed on NYSE-Euronext Paris, TxCell is a spin-off of Inserm (France’s National Institute for Health and Medical Research). TxCell has 68 employees based both at the headquarters located in the Sophia Antipolis technology park, Nice, France and at its manufacturing site in Besançon. For further information visit www.txcell.com
Help employers find you! Check out all the jobs and post your resume.
